Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes

Journal of Atherosclerosis and Thrombosis

Volumn 25, Issue 6, 2018, Pages 467-476

  Sugiyama, Seigo ^a   Jinnouchi, Hideaki ^a,b   Kurinami, Noboru ^a   Hieshima, Kunio ^a   Yoshida, Akira ^a   Jinnouchi, Katsunori ^a   Nishimura, Hiroyuki ^a   Suzuki, Tomoko ^a   Miyamoto, Fumio ^a   Kajiwara, Keizo ^a   Jinnouchi, Tomio ^a  

^a Jinnouchi Hospital   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Fat mass; Muscle mass; Sarcopenia; Sodium glucose co transporter 2 inhibitor; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE; ALPHA GLUCOSIDASE INHIBITOR; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; NON SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT LOSS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETIC OBESITY; DYSLIPIDEMIA; FAT MASS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPEDANCE; IMPEDANCE SPECTROSCOPY; LEAN BODY WEIGHT; MALE; MUSCLE MASS; NON INSULIN DEPENDENT DIABETES MELLITUS; PARASPINAL MUSCLE; PSOAS MUSCLE; SKELETAL MUSCLE; SMOKING; WAIST CIRCUMFERENCE; ADIPOSE TISSUE; DRUG EFFECT; METABOLISM; MIDDLE AGED; OBESITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY;

ADIPOSE TISSUE; ADIPOSITY; BENZHYDRYL COMPOUNDS; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 85047990255     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.40873     Document Type: Article

References (32)

1. Scheen AJ and Van Gaal LF: Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol, 2014; 2: 911-922
2. Shulman GI: Ectopic fat in insulin resistance, dyslipid-emia, and cardiometabolic disease. N Engl J Med, 2014; 371: 1131-1141
3. Bianchi L and Volpato S: Muscle dysfunction in type 2 diabetes: a major threat to patient’s mobility and independence. Acta Diabetol, 2016; 53: 879-889
4. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J and Parikh S: Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab, 2012; 97: 1020-1031
5. Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsu-nomiya K, Iwamoto Y, Watada H, Ohtsuka W, Watanabe D, Suganami H, Tofogliflozin and Study g: Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Phar-macother, 2014; 15: 749-766
6. Blonde L, Stenlof K, Fung A, Xie J, Canovatchel W and Meininger G: Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med, 2016; 128: 371-380
7. Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I and Barnett AH: Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network metaanalysis. Diabetes Obes Metab, 2014; 16: 433-442
8. Vivian EM: Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Am J Health Syst Pharm, 2015; 72: 361-372
9. Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, Sugg J and Parikh S: Dapa-gliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab, 2014; 16: 159-169
10. Kostev K, Pscherer S, Rist R, Busch S and Scheerer MF: Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes. J Diabetes Sci Technol, 2016;1932296816688011
11. Scheerer MF, Rist R, Proske O, Meng A and Kostev K: Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study. Diabetes Metab Syndr Obes, 2016; 9: 337-345
12. Hesselink MK, Schrauwen-Hinderling V and Schrauwen P: Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus. Nat Rev Endocrinol, 2016; 12: 633-645
13. Fujita Y and Inagaki N: Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Investig, 2014; 5: 265-275
14. Bouchi R, Terashima M, Sasahara Y, Asakawa M, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, Izu-miyama H, Hashimoto K, Yoshimoto T and Ogawa Y: Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study. Cardiovasc Diabe-tol, 2017; 16: 32
15. Cetrone M, Mele A and Tricarico D: Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type E. Curr Diabetes Rev, 2014; 10: 231-237
16. Malavolti M, Mussi C, Poli M, Fantuzzi AL, Salvioli G, Battistini N and Bedogni G: Cross-calibration of eight-polar bioelectrical impedance analysis versus dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21-82 years. Ann Hum Biol, 2003; 30: 380-391
17. Kurinami N, Sugiyama S, Yoshida A, Hieshima K, Miyamoto F, Kajiwara K, Jinnouchi T and Jinnouchi H: Correlation of body muscle/fat ratio with insulin sensitivity using hyperinsulinemic-euglycemic clamp in treatmentnaive type 2 diabetes mellitus. Diabetes Res Clin Pract, 2016; 120: 65-72
18. Wannamethee SG and Atkins JL: Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity. Proc Nutr Soc, 2015; 74: 405-412
19. Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Ham-mad A, Tamai Y, Inagaki N and Uemoto S: Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. Nutrition, 2016; 32: 1200-1205
20. Aubrey J, Esfandiari N, Baracos VE, Buteau FA, Frenette J, Putman CT and Mazurak VC: Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol (Oxf), 2014; 210: 489-497
21. Brons C and Grunnet LG: MECHANISMS IN ENDOCRINOLOGY: Skeletal muscle lipotoxicity in insulin resistance and type 2 diabetes: a causal mechanism or an innocent bystander? Eur J Endocrinol, 2017; 176: R67-R78
22. Traina SB, Slee A, Woo S and Canovatchel W: The Importance of Weight Change Experiences for Performance of Diabetes Self-Care: A Patient-Centered Approach to Evaluating Clinical Outcomes in Type 2 Diabetes. Diabetes Ther, 2015; 6: 611-625
23. Obata A, Kubota N, Kubota T, Iwamoto M, Sato H, Sak-urai Y, Takamoto I, Katsuyama H, Suzuki Y, Fukazawa M, Ikeda S, Iwayama K, Tokuyama K, Ueki K and Kadowaki T: Tofogliflozin Improves Insulin Resistance in Skeletal Muscle and Accelerates Lipolysis in Adipose Tissue in Male Mice. Endocrinology, 2016; 157: 1029-1042
24. Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, Sica D, Rothenberg P and Plum-Morschel L: Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab, 2014; 16: 1087-1095
25. Solini A: Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Acta Diabetol, 2016; 53: 863-870
26. Hirose S, Nakajima S, Iwahashi Y, Seo A, Takahashi T and Tamori Y: Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus. Intern Med, 2016; 55: 3239-3245
27. Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD and Ferrannini E: Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care, 2015; 38: 1730-1735
28. Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, Xiong J, Perez Z, Norton L, Abdul-Ghani MA and DeFronzo RA: Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest, 2014; 124: 509-514
29. Komiya H, Mori Y, Yokose T, Kurokawa N, Horie N and Tajima N: Effect of intramuscular fat difference on glucose and insulin reaction in oral glucose tolerance test. J Atheroscler Thromb, 2006; 13: 136-142
30. Sano M, Meguro S, Kawai T and Suzuki Y: Increased grip strength with sodium-glucose cotransporter 2. J Diabetes, 2016; 8: 736-737
31. Ribola FA, Cancado FB, Schoueri JH, De Toni VF, Medeiros VH and Feder D: Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci, 2017; 21: 199-211
32. Hsu WC, Araneta MR, Kanaya AM, Chiang JL and Fuji-moto W: BMI cut points to identify at-risk Asian Americans for type 2 diabetes screening. Diabetes Care, 2015; 38: 150-158